Literature DB >> 9187105

FHIT gene expression in human ovarian, endometrial, and cervical cancer cell lines.

D T Hendricks1, R Taylor, M Reed, M J Birrer.   

Abstract

The fragile histidine triad (FHIT) gene, located at 3p14.2, has been shown to be altered in numerous epithelial cancers. Because previous studies have shown a loss of heterozygosity and cytogenetic abnormalities at the 3p region in ovarian, endometrial, and cervical carcinomas, we examined the status of the FHIT gene in 14 ovarian, 8 cervical, and 4 endometrial human cancer cell lines. RNA was isolated and subjected to reverse transcription-PCR to amplify the FHIT gene transcript. Sixty-three % (5 of 8) of cervical cell lines, 14% (2 of 14) of ovarian cell lines, and none (0 of 4) of the endometrial cell lines displayed aberrantly migrating FHIT transcripts. DNA sequencing demonstrated that the aberrantly migrating bands primarily lacked exons 5, 6, and 7 (with other exon losses also observed), resulting in shorter mRNA transcripts. Southern blot analysis of DNA from five of the cervical carcinomas demonstrated alterations in four of them, three of which had exhibited no normally sized FHIT transcripts. The results suggest that the expression of the FHIT gene may be altered in cervical tumor tissue, potentially implicating this gene in cervical tumorigenesis, whereas the involvement of this gene appears to be less important in the development of ovarian and endometrial cancer.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9187105

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  16 in total

1.  Control of 5',5'-dinucleoside triphosphate catabolism by APH1, a Saccharomyces cerevisiae analog of human FHIT.

Authors:  J Chen; A Brevet; S Blanquet; P Plateau
Journal:  J Bacteriol       Date:  1998-05       Impact factor: 3.490

2.  Muir-Torre-like syndrome in Fhit-deficient mice.

Authors:  L Y Fong; V Fidanza; N Zanesi; L F Lock; L D Siracusa; R Mancini; Z Siprashvili; M Ottey; S E Martin; T Druck; P A McCue; C M Croce; K Huebner
Journal:  Proc Natl Acad Sci U S A       Date:  2000-04-25       Impact factor: 11.205

3.  Replacement of Fhit in cancer cells suppresses tumorigenicity.

Authors:  Z Siprashvili; G Sozzi; L D Barnes; P McCue; A K Robinson; V Eryomin; L Sard; E Tagliabue; A Greco; L Fusetti; G Schwartz; M A Pierotti; C M Croce; K Huebner
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-09       Impact factor: 11.205

4.  Inhibition of the Receptor Tyrosine Kinase AXL Restores Paclitaxel Chemosensitivity in Uterine Serous Cancer.

Authors:  Marguerite L Palisoul; Jeanne M Quinn; Emily Schepers; Ian S Hagemann; Lei Guo; Kelsey Reger; Andrea R Hagemann; Carolyn K McCourt; Premal H Thaker; Matthew A Powell; David G Mutch; Katherine C Fuh
Journal:  Mol Cancer Ther       Date:  2017-09-13       Impact factor: 6.261

5.  Abnormal Fhit expression is an independent poor prognostic factor for cervical cancer.

Authors:  S Takizawa; S Nakagawa; K Nakagawa; T Yasugi; T Fujii; K Kugu; T Yano; H Yoshikawa; Y Taketani
Journal:  Br J Cancer       Date:  2003-04-22       Impact factor: 7.640

6.  The aryl hydrocarbon receptor repressor is a putative tumor suppressor gene in multiple human cancers.

Authors:  Enrique Zudaire; Natalia Cuesta; Vundavalli Murty; Karen Woodson; Lisa Adams; Nieves Gonzalez; Alfredo Martínez; Gopeshwar Narayan; Ilan Kirsch; Wilbur Franklin; Fred Hirsch; Michael Birrer; Frank Cuttitta
Journal:  J Clin Invest       Date:  2008-02       Impact factor: 14.808

Review 7.  Fragile histidine triad protein: structure, function, and its association with tumorogenesis.

Authors:  Md Imtaiyaz Hassan; Abdullah Naiyer; Faizan Ahmad
Journal:  J Cancer Res Clin Oncol       Date:  2009-12-24       Impact factor: 4.553

8.  Multiple Patterns of FHIT Gene Homozygous Deletion in Egyptian Breast Cancer Patients.

Authors:  Heba M S Ismail; Amina M Medhat; Amr M Karim; Nadia I Zakhary
Journal:  Int J Breast Cancer       Date:  2011-10-19

Review 9.  Epigenetics of cervical cancer. An overview and therapeutic perspectives.

Authors:  Alfonso Dueñas-González; Marcela Lizano; Myrna Candelaria; Lucely Cetina; Claudia Arce; Eduardo Cervera
Journal:  Mol Cancer       Date:  2005-10-25       Impact factor: 27.401

10.  Activation state-dependent interaction between Gαq subunits and the Fhit tumor suppressor.

Authors:  Hao Zuo; Grace P W Chan; Jing Zhu; Wendy W S Yeung; Anthony S L Chan; Hermann Ammer; Yung H Wong
Journal:  Cell Commun Signal       Date:  2013-08-15       Impact factor: 5.712

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.